Name: Toumai (Toumai SP)
Brand: MicroPort MedBot (HKEX: 2252)

Who's exposed

Jobs in the threat radius

surgical first assistant (laparoscopic and urologic procedures)
operating room scrub / circulating nurse (standardized robotic-workflow procedures)
laparoscopic surgeon performing high-volume routine procedures

Deployment status

Shipping and commercially installed, with more than 200 global installations and over 300 cumulative orders across 60+ countries and regions as of 2026 — the fastest-scaling non-Intuitive surgical robot platform globally, and by domestic Chinese trade coverage, now ahead of da Vinci in new Chinese hospital installations for the Jan-May 2026 period specifically (not global share, where Intuitive's 11,700+ installed base still leads by a wide margin). Real telesurgery use, not just local operation: Toumai performed the UK's first telesurgery procedure in March 2026, following the first intra-EU telesurgery between two Belgian hospitals roughly six months earlier. It holds marketing approval in around 20 countries and is, per the manufacturer, the only surgical robot cleared for remote surgical use in the EU.

When this hits the labor market

3-5 years for standardized, high-volume laparoscopic procedures (routine urologic and general-surgery cases) in the markets where Toumai is displacing both open surgery and rival robotic platforms on price — this is where the surgical-assistant and scrub-role headcount-per-procedure math shifts first. 5-10 years for the telesurgery angle to meaningfully change where surgeons practice: remote/rural hospitals gaining specialist access without a specialist physically present changes the geography of surgical labor before it changes the headcount, and regulatory approval for remote surgery remains uneven outside the EU and China.

The surgical robot this catalog was missing

Every surgical robot in this catalog until now has been American, European, or Japanese — Intuitive’s da Vinci Xi and da Vinci 5, Stryker’s Mako, Medtronic’s Hugo, CMR’s Versius, Medicaroid’s hinotori. That was a real gap, not a stylistic one: MicroPort MedBot’s Toumai is now past 200 global installations and 300 cumulative orders across more than 60 countries, and Chinese trade coverage puts it ahead of da Vinci in new domestic hospital installations for early 2026 — a genuine head-of-market claim in the world’s second-largest healthcare market, not a startup’s press release.

What it does and where it’s approved

Toumai comes in two configurations: a multi-arm patient-cart system for general laparoscopic and urologic work, and Toumai SP, a single-port variant that reduces the number of incisions for select procedures. Both carry 3D high-definition visualization and support urology, general surgery, gynecology, and thoracic cases. The platform holds NMPA approval in China and marketing clearance in roughly 20 countries, and — per the manufacturer — is the only surgical robot cleared for remote surgical use in the EU.

That telesurgery capability isn’t a spec-sheet claim sitting unused. In March 2026, a surgeon in the UK performed the country’s first telesurgery procedure on Toumai. That followed the first intra-EU telesurgery, between two Belgian hospitals, roughly six months earlier. The system operates over 5G, dedicated fiber, standard broadband, or satellite links, which is the part of the story that matters more than any single procedure count: a surgeon in one city operating on a patient in another, through a robot, is a different labor geography than a surgeon and patient in the same room.

Why we care for LostJobs

Most of this catalog’s surgical entries compete on precision and dexterity inside one operating room. Toumai’s more interesting angle for career intelligence is what telesurgery does to where surgical expertise has to physically sit. If a specialist in a major city can operate on a patient in a hospital without one, on Toumai’s own infrastructure, that doesn’t eliminate the surgeon’s job — it relocates where that expertise is needed, the same displacement-not-elimination pattern this catalog has already tracked in remote aviation and driverless trucking, just applied to the highest-skill profession in the book.

The more immediate pressure, though, is on the team around the surgeon rather than the surgeon. Standardized robotic workflows reduce the headcount needed per procedure for scrub and circulating roles, and Toumai’s price positioning against da Vinci — undercutting it enough to win share in China and expand into more than 60 countries in a few years — means that pressure is arriving in more hospitals, faster, than a single premium-priced Western platform would produce on its own. We’re cataloging Toumai now because a platform that’s already reshaping who gets access to a robotic-surgery-equipped OR, and increasingly to a surgeon who isn’t in the building, is a career-intelligence story regardless of headline procedure counts.